Skip to main content
Log in

DPP4 Inhibitors: a new approach in diabetes treatment

  • Review
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

The role of dipeptidyl peptidase-IV (DPP4) as both a regulatory enzyme and a signalling factor has been evaluated and described in many studies. DPP4 inhibition results in increased blood concentration of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). This causes an increase in glucose-dependent stimulation of insulin secretion, resulting in a lowering of blood glucose levels. Recent studies have shown that DPP4 inhibitors can induce a significant reduction in glycosylated haemoglobin (HbA1c) levels, either as monotherapy or as a combination with other antidiabetic agents. Research has also demonstrated that DPP4 inhibitors portray a very low risk of hypoglycaemia development. This review article focuses on the two leading agents of this category (sitagliptin and vildagliptin), providing an overview of their function along with the latest data regarding their clinical efficacy as antidiabetic agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. CDC web site. Diabetes and gestational diabetes trends among adults in the United States. Available at: www.cdc.gov., Accessed June 2008.

  2. Zinman B. Translating the Diabetes Control and Complications Trial (DCCT) into clinical practice: overcoming the barriers. Diabetologia. 1997;40(suppl 2):S88–S90.

    Article  Google Scholar 

  3. Elrick H, Stimmler L, Hlad CJ Jr, et al. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab. 1964;24:1076–1082.

    PubMed  CAS  Google Scholar 

  4. Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest. 1967;46:1954–1962.

    PubMed  CAS  Google Scholar 

  5. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003;26:2929–2940.

    Article  PubMed  CAS  Google Scholar 

  6. Vilsboll T, Holst JJ. Incretins, insulin secretion and type-2 diabetes mellitus. Diabetologia. 2004;47:357–366.

    Article  PubMed  CAS  Google Scholar 

  7. Xu G, Stoffers DA, Habener JF, et al. Exendin 4 stimulates both b-cell replication and neogenesis, resulting in increased b-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48:2270–2276.

    Article  PubMed  CAS  Google Scholar 

  8. Farilla L, Hui H, Bertolotto C, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology. 2002;143:4397–4408.

    Article  PubMed  CAS  Google Scholar 

  9. Perfetti R, Hui H. The role of GLP-1 in the life and death of pancreatic beta cells. Horm Metab Res. 2004;36:804–810.

    Article  PubMed  CAS  Google Scholar 

  10. Nauck M, Stockmann F, Ebert R, et al. Reduced incretin effect in type 2 (noninsulin-dependent) diabetes. Diabetologia. 1986;29:46–52.

    Article  PubMed  CAS  Google Scholar 

  11. Drucker DJ, Philippe J, Mojsov S, et al. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A. 1987;84:3434–3438.

    Article  PubMed  CAS  Google Scholar 

  12. Ahren B. DPP-4 inhibitors. Best Pract Res Clin Endocrinol Metab. 2007;21:517–533.

    Article  PubMed  CAS  Google Scholar 

  13. Nystrom T, Gutniak M, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type-2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004;287:E1209–E1215.

    Article  PubMed  CAS  Google Scholar 

  14. Qi SY, Riviere PJ, Trojnar J, et al. Cloning and characterization of dipeptidyl peptidase 10, a new member of an emerging subgroup of serine proteases. Biochem J. 2003;373:179–189.

    Article  PubMed  CAS  Google Scholar 

  15. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–1705.

    Article  PubMed  CAS  Google Scholar 

  16. Deacon CF. Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes. Expert Opin Investig Drugs. 2007;16:533–545.

    Article  PubMed  CAS  Google Scholar 

  17. Byettal (exenatide) [package insert]. San Diego, CA: Amylin Pharmaceuticals; 2007.

  18. Barnett A. Exenatide. Expert Opin Pharmacother. 2007;8:2593–2608.

    Article  PubMed  CAS  Google Scholar 

  19. Mikhail N. Exenatide: a novel approach for treatment of type 2 diabetes. South Med J. 2006;99:1271–1279.

    PubMed  Google Scholar 

  20. Lambeir AM, Durinx C, Scharpe S, et al. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 2003;40:209–294.

    Article  PubMed  CAS  Google Scholar 

  21. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept. 1999;85:9–24.

    Article  PubMed  CAS  Google Scholar 

  22. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl peptidase IV, hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993;214:829–835.

    Article  PubMed  CAS  Google Scholar 

  23. Deacon CF, Johnson AH, Holst JJ. Degradation of glucagon-like hydrolyzes substance peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab. 1995;80:952–957.

    Article  PubMed  CAS  Google Scholar 

  24. Deacon CF, Nauck MA, Toft-Nielsen M, et al. Both subcutaneously and intravenously administered glucagon like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995;44:1126–1131.

    Article  PubMed  CAS  Google Scholar 

  25. Deacon CF, Pridal L, Klarskov L, et al. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol. 1996;271:E458–464.

    PubMed  CAS  Google Scholar 

  26. Kieffer TJ, McIntosh CHS, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology. 1995;136:3585–3596.

    Article  PubMed  CAS  Google Scholar 

  27. Pauly RP, Rosche F, Wermann, et al. Biological Demuth H-U. Investigation of glucose-dependent insulinotropic polypeptide-(1–42) and glucagon-like peptide-1-(3–36) degradation in vitro by dipeptidyl peptidase IV using matrixassisted Laser desorption/ionization-time of flight mass spectrometry. J Biol Chem. 1996;271:23222–23229

    Article  PubMed  CAS  Google Scholar 

  28. Siegel EG, Gallwitz B, Scharf G, et al. Biological activity of GLP-1-analogues with N-terminal modifications. Regul Pept. 1999;79:93–102.

    Article  PubMed  CAS  Google Scholar 

  29. Hupe-Sodmann K, McGregor GP, Bridenbaugh R, et al. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7–36)amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept. 1995;58:149–156.

    Article  PubMed  CAS  Google Scholar 

  30. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract. 2006;60:1454–1470.

    Article  PubMed  CAS  Google Scholar 

  31. Villhauer EB, Brinkman JA, Naderi GB, et al. 1-[[(3-hydroxy-1-adamantyl) amino-]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycaemic properties. J Med Chem. 2003;46:2774–2789.

    Article  PubMed  CAS  Google Scholar 

  32. Augeri DJ, Robl JA, Betebenner DA, et al. Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem. 2005;48:5025–5037.

    Article  PubMed  CAS  Google Scholar 

  33. Kim D, Wang L, Beconi M, et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-rifluorophenyl) butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem. 2005;48:141–151.

    Article  PubMed  CAS  Google Scholar 

  34. Mu J, Woods J, Zhou YP, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes. 2006;55:1695–1704.

    Article  PubMed  CAS  Google Scholar 

  35. Ahren B, Sorhede Winzell M, Burkey B, et al. Beta-cell expression of a dominantnegative HNF-1 alpha compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in mice. Eur J Pharmacol. 2005;521:164–168.

    Article  PubMed  CAS  Google Scholar 

  36. He YL, Sabo R, Campestrini J, et al. The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin. Eur J Clin Pharmacol. 2007;63:677–686.

    Article  PubMed  CAS  Google Scholar 

  37. Herman GA, Bergman A, Liu F, et al. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol. 2006;46:876–886.

    Article  PubMed  CAS  Google Scholar 

  38. Ahren B, Gomis R, Standl E, et al. Twelve and 52-week efficacy of the dipeptidyl peptidase IV LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2874–2880.

    Article  PubMed  CAS  Google Scholar 

  39. Bergman AJ, Stevens C, Zhou Y, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomised, placebo-controlled study in healthy male volunteers. Clin Ther. 2006;28:55–72.

    Article  PubMed  CAS  Google Scholar 

  40. He YL, Sadler BM, Sabo R, et al. The absolute oral bioavailability and populationbased pharmacokinetic modelling of a novel dipeptidyl peptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet. 2007;46:787–802.

    Article  PubMed  CAS  Google Scholar 

  41. Hanefeld M, Herman GA, Wu M, et al. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin. 2007;23:1329–1339.

    Article  PubMed  CAS  Google Scholar 

  42. Gallwitz B. Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes. Drugs Today (Barc). 2007;43:801–814.

    CAS  Google Scholar 

  43. Miller S, St Onge EL. Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Ann Pharmacother. 2006;40:1336–1343.

    Article  PubMed  CAS  Google Scholar 

  44. Herman GA, Bergmann J, Wagner JA. Sitagliptin, a DPP-4 inhibitor: an overview of the pharmacokinetic (PK) profile and the propensity for drug-drug interactions (DDI). Diabetologia. 2006;49:481.

    Article  CAS  Google Scholar 

  45. Herman GA, Bergman A, Yi B, et al. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Curr Med Res Opin. 2006;22:1939–1947.

    Article  PubMed  CAS  Google Scholar 

  46. Goldstein BJ, Feinglos MN, Lunceford JK, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycaemic control in patients with type 2 diabetes. Diabetes Care. 2007;30:1979–1987.

    Article  PubMed  CAS  Google Scholar 

  47. Miller JL, Migoya E, Talaty JE. The effect of MK-0431 on the pharmacokinetics of digoxin after concomitant administration for 10 days in healthy subjects. Clin Pharmacol Ther. 2006;79:24.

    Article  Google Scholar 

  48. He Y-L, Wang Y, Bullock JM, et al. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol. 2007;47:633–641.

    Article  PubMed  CAS  Google Scholar 

  49. He YL, Sabo R, Balez S, et al. The absolute oral bioavailability and populationbased pharmacokinetic modelling of a novel dipeptidyl peptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet. 2007;46:787–802.

    Article  PubMed  CAS  Google Scholar 

  50. Barilla D, He Y, Balez S, et al. No pharmacokinetic interactions or acute clinical safety issues preclude combination of the DPP-4 inhibitor LAF237 with glyburide. Diabetes. 2004;53(suppl 2):470.

    Google Scholar 

  51. He YL, Sabo R, Picard F, et al. Lack of pharmacokinetic interaction between vildagliptin and metformin in patients with type 2 diabetes. Clin Pharmacol Ther. 2006;79:62.

    Article  CAS  Google Scholar 

  52. Serra DB, He YL, Wang Y, et al. Combination of the DPP-4 inhibitor vildagliptin (LAF237) with pioglitazone is safe and well tolerated with no pharmacokinetic interaction. Diabetes. 2005;54(suppl 1):528–529.

    Google Scholar 

  53. Hanefeld M, Herman G, Mickel C, et al. Effect of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, on glycaemic control after 12 weeks in patients with type-2 diabetes. Diabetologia. 2005;49 (suppl 1):A287.

    Google Scholar 

  54. Scott R, Wu L, Sanchez M, et al. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type-2 diabetes. Int J Clin Pract. 2007;61:171–180.

    Article  PubMed  CAS  Google Scholar 

  55. Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycaemic control in patients with type-2 diabetes. Diabetes Care. 2006;29:2632–2637.

    Article  PubMed  CAS  Google Scholar 

  56. Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type-2 diabetes mellitus. Diabetologia. 2006;49:2564–2571.

    Article  PubMed  CAS  Google Scholar 

  57. Rosenstock J, Baron MA, Dejager S, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomised trial. Diabetes Care. 2007;30:217–223.

    Article  PubMed  CAS  Google Scholar 

  58. Schweizer A, Couturier A, Foley JE, et al. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes. Diabet Med. 2007;24:955–961.

    Article  PubMed  CAS  Google Scholar 

  59. Ahren B, Landin-Olsson M, Jansson PA, et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type-2 diabetes. J Clin Endocrinol Metab. 2004;89:2078–2084.

    Article  PubMed  CAS  Google Scholar 

  60. Ristic S, Byiers S, Foley J, et al. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab. 2005;7:692–698.

    Article  PubMed  CAS  Google Scholar 

  61. Pi-Sunyer FX, Schweizer A, Mills D, et al. Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type-2 diabetes. Diabetes Res Clin Pract. 2007;76:132–138.

    Article  PubMed  CAS  Google Scholar 

  62. Scherbaum WA, Schweizer A, Mari A, et al. Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab. 2008;Feb 1 [Epub ahead of print].

  63. Brazg R, Xu L, Dalla Man C, et al. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin of 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9:186–193.

    Article  PubMed  CAS  Google Scholar 

  64. Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29:2638–2643.

    Article  PubMed  CAS  Google Scholar 

  65. Rosenstock J, Brazg R, Andryuk PJ, et al. Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomised, doubleblind, placebo-controlled, parallel-group study. Clin Ther. 2006;28:1556–1568.

    Article  PubMed  CAS  Google Scholar 

  66. Jago C. American Diabetes Association. Updates on drug treatments-66th Scientific Sessions 9–13 June 2006, Washington, DC, USA. IDrugs. 2006;9:538–541.

    PubMed  Google Scholar 

  67. Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007;9:733–745.

    Article  PubMed  CAS  Google Scholar 

  68. Ahren B, Pacini G, Foley JE, et al. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type-2 diabetes over 1 year. Diabetes Care. 2005;28:1936–1940.

    Article  PubMed  CAS  Google Scholar 

  69. Balas B, Baig MR, Watson C, et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab. 2007;92:1249–1255.

    Article  PubMed  CAS  Google Scholar 

  70. Garber AJ, Schweizer A, Baron MA, et al. Vildagliptin in combination with pioglitazeone improves glycaemic control in patients with type-2 diabetes failing thiazolidinedione monotherapy: a randomised, placebo-controlled study. Diab Obes Metab. 2007;9:166–174.

    Article  CAS  Google Scholar 

  71. Rosenstock J, Baron MA, Camisasca RP, Couturier A et, al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diab Obes Metab. 2007;9:175–185.

    Article  CAS  Google Scholar 

  72. Garber AJ, Foley JE, Banerji MA, et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab. 2008; Feb 18 [Epub ahead of print].

  73. Fonseca V, Schweizer A, Albrecht D, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007;50:1148–1155.

    Article  PubMed  CAS  Google Scholar 

  74. Janumet (exenatide) [package insert]. Whitehouse Station, NJ: Merck & Co; 2008.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Aristidis Veves.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Doupis, J., Veves, A. DPP4 Inhibitors: a new approach in diabetes treatment. Adv Therapy 25, 627–643 (2008). https://doi.org/10.1007/s12325-008-0076-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-008-0076-1

Keywords

Navigation